CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NewAmsterdam Pharma Company NV is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NewAmsterdam Pharma Company NV
Gooimeer 2-35
Phone: +31 352062971p:+31 352062971 NAARDEN, 1411 DC  Netherlands Ticker: NAMSNAMS
Business Summary
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board William H.Lewis 55 1/4/2024 1/4/2024
Chief Executive Officer, Executive Director Michael H.Davidson 67 11/1/2022 11/1/2022
Interim Chief Financial Officer LouiseKooij 3/1/2023 3/1/2023
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
PCI Pharma Midco UK Limited Wye Valley Business Park Brecknockshire United Kingdom
Pioneer UK Midco 1 Limited Wye Valley Business Park Brecknockshire United Kingdom
CCHN Group Holdings, Inc. 9201 E. Mountain View Scottsdale AZ United States
11 additional Subsidiary records available in full report.

Business Names
Business Name
AndersonBrecon
Apex Foot Heath Industries, LLC
Biocerna LLC
44 additional Business Names available in full report.

General Information
Number of Employees: 62 (As of 9/30/2024)
Outstanding Shares: 92,385,872 (As of 10/31/2024)
Shareholders: 30
Stock Exchange: NASD
Federal Tax Id: 981562203


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024